Brief: SSY Group Obtains China's NMPA Approval For Emedastine Difumarate Eye Drops 0.05% Type 4, Others
21/05/2026 10:30
May 21 (Reuters) - SSY Group Ltd 2005.HK: OBTAINS NMPA APPROVAL FOR EMEDASTINE DIFUMARATE EYE DROPS 0.05% TYPE 4 OBTAINS NMPA APPROVAL FOR PERAMIVIR AND SODIUM CHLORIDE INJECTION 100ML TYPE 4 OBTAINS NMPA APPROVAL FOR PERINDOPRIL ARGININE TABLETS 5MG TYPE 4 OBTAINS NMPA APPROVAL FOR BUMETANIDE INJECTION 1ML: 0.5G TYPE 3 Further company coverage: 2005.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SSY
See all newsBrief: SSY Group Receives NMPA China Approval For Sodium Cromoglicate Eye Drops 2%
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth